Association between variants in TCF7L2 , CTRB1/2 , and GLP-1R genes and response to therapy with glucagon-like peptide-1 receptor agonists.

There is no evidence suggesting a role for the variants studied in response to GLP-1 RA therapy in people with T2DM. However, specific demographic and clinical factors may be related to a better response to treatment with these agents.